Valuation: Pharmigene, Inc.

Market Cap 452M 13.94M 12.18M 11.24M 10.36M 19.53M 1.34B 19.96M 134M 52.84M 657M 52.34M 51.19M 2.26B P/E 2024
-8.68x
P/E 2025 -6.84x
Enterprise Value 1.02B 31.51M 27.54M 25.41M 23.43M 44.15M 3.03B 45.13M 304M 119M 1.49B 118M 116M 5.12B EV / Sales 2024
10.1x
EV / Sales 2025 5.35x
Free-Float
49.29%
Yield 2024 *
-
Yield 2025 -
1 day+10.49%
1 week+42.52%
Current month+23.11%
1 month+9.15%
3 months-12.25%
6 months-10.95%
Current year-9.60%
1 week 5.9
Extreme 5.9
9.24
1 month 5.9
Extreme 5.9
9.24
Current year 5.9
Extreme 5.9
11.85
1 year 5.9
Extreme 5.9
14.1
3 years 5.9
Extreme 5.9
25.7
5 years 5.9
Extreme 5.9
25.7
10 years 5.9
Extreme 5.9
36
Manager TitleAgeSince
Chief Executive Officer 67 03/11/2019
Chief Operating Officer 49 03/11/2019
Comptroller/Controller/Auditor - -
Director TitleAgeSince
Director/Board Member 76 23/11/2020
Director/Board Member 49 03/11/2019
Chairman 67 -
Change 5-day change 1-year change 3-year change Capi.($)
+10.49%+42.52%-21.15%-60.49% 13.94M
-0.15%+3.79%+151.51%+98.56% 4.72B
+3.71%+8.83%+120.60%+201.98% 3.67B
+7.30%+18.20%+124.22%-38.65% 2.23B
-1.51%+39.35%+233.45%+285.35% 2.05B
-5.50%-0.75%-29.67%-37.76% 2.04B
+2.12%+18.88%+197.94%-41.99% 1.07B
-2.39%-1.55%-10.78%+35.95% 875M
-4.16%+6.17%-34.21%-11.74% 513M
-3.06%-3.18%-3.97% - 476M
Average +0.68%+13.17%+72.79%+47.91% 1.77B
Weighted average by Cap. +0.66%+10.78%+115.32%+93.63%

Financials

2024 2025
Net sales 117M 3.6M 3.14M 2.9M 2.67M 5.04M 346M 5.15M 34.66M 13.63M 170M 13.51M 13.21M 584M 200M 6.17M 5.39M 4.97M 4.59M 8.64M 594M 8.83M 59.46M 23.39M 291M 23.17M 22.66M 1B
Net income -82.86M -2.56M -2.23M -2.06M -1.9M -3.58M -246M -3.66M -24.65M -9.69M -121M -9.6M -9.39M -415M -73M -2.25M -1.97M -1.82M -1.67M -3.16M -217M -3.23M -21.71M -8.54M -106M -8.46M -8.27M -366M
Net Debt 458M 14.13M 12.35M 11.39M 10.5M 19.79M 1.36B 20.23M 136M 53.56M 666M 53.06M 51.89M 2.29B 570M 17.58M 15.36M 14.17M 13.07M 24.63M 1.69B 25.17M 169M 66.64M 829M 66.01M 64.56M 2.85B
Logo Pharmigene, Inc.
Pharmigene Inc is mainly engaged in drug gene diagnosis, functional medical testing services and agency sales of laboratory equipment and consumables. The Company mainly engages in field of genomics science, developing professional drug genetic diagnostic kits, testing technologies, and overall solutions for the research and development of drug genomics in precision medicine. The Company's molecular diagnostic products mainly include AutoEx16 automatic nucleic acid extractor, Clopidogrel drug effectiveness gene CYP2C19*2&*3 test kit, SGE 1502 test suite, SGE 3101 test suite, SGE 5701 test suite, Sega 5801 test kit, SGE B27 test kit, SGE whole blood calculation and extraction kit and others. Testing services include drug genetic testing projects, functional medical testing projects and personalized genetic testing. The Company mainly distributes its products in Taiwan market and other markets.
Employees
-
Date Price Change Volume
17/07/26 NT$8.950 +10.49% 255,559
16/07/26 NT$8.100 +28.57% 385,871
15/07/26 NT$6.300 +3.45% 32,071
14/07/26 NT$6.090 -4.40% 55,153
13/07/26 NT$6.370 +1.43% 279,328
  1. Stock Market
  2. Stocks
  3. 7595 Stock